eMedicine Specialties > Oncology > Carcinomas of the Genitourinary Tract

Transitional Cell Carcinoma, Renal: Multimedia

Author: Georgi Guruli, MD, PhD, Consulting Staff, Department of Surgery, Division of Urology, University Hospital; Assistant Professor, Department of Surgery, Division of Urology, UMDNJ - New Jersey Medical School
Coauthor(s): Badrinath R Konety, MD, Associate Professor, Department of Urology, University of California at San Francisco
Contributor Information and Disclosures

Updated: Jul 27, 2006

Multimedia

CT scan with contrast, vascular phase. Mass can b...
(Enlarge Image)
Media file 1: CT scan with contrast, vascular phase. Mass can be seen in the left renal pelvis (black arrows). Patient underwent nephroureterectomy. Tumor was high-grade urothelial carcinoma invading subepithelial tissue (stage T1) and measuring 7.5 X 3.2 X 3 cm.
[ CLOSE WINDOW ]
CT scan with contrast, vascular phase. Mass can b...

CT scan with contrast, vascular phase. Mass can be seen in the left renal pelvis (black arrows). Patient underwent nephroureterectomy. Tumor was high-grade urothelial carcinoma invading subepithelial tissue (stage T1) and measuring 7.5 X 3.2 X 3 cm.

CT scan of the same patient as in Image 1, delay...
(Enlarge Image)
Media file 2: CT scan of the same patient as in Image 1, delayed phase. Enhancing mass can be visualized in the left renal pelvis (white arrows).
[ CLOSE WINDOW ]
CT scan of the same patient as in Image 1, delay...

CT scan of the same patient as in Image 1, delayed phase. Enhancing mass can be visualized in the left renal pelvis (white arrows).

Retrograde pyelography. Filling defect can be see...
(Enlarge Image)
Media file 3: Retrograde pyelography. Filling defect can be seen in the left renal pelvis and lower calix (black arrows). Patient underwent left nephroureterectomy. Tumor was low-grade urothelial carcinoma measuring 2.5 X 2 X 1 cm.
[ CLOSE WINDOW ]
Retrograde pyelography. Filling defect can be see...

Retrograde pyelography. Filling defect can be seen in the left renal pelvis and lower calix (black arrows). Patient underwent left nephroureterectomy. Tumor was low-grade urothelial carcinoma measuring 2.5 X 2 X 1 cm.

This radiograph shows a right retrograde pyelogra...
(Enlarge Image)
Media file 4: This radiograph shows a right retrograde pyelogram demonstrating a large filling defect in the mid-ureter due to transitional cell carcinoma (large arrow). Note the characteristic appearance of radiographic contrast material just distal to the obstruction (small arrow), which gives rise to the so-called goblet sign. Contrast is also visible beyond the partially obstructed segment of the ureter in the renal pelvis and collecting system.
[ CLOSE WINDOW ]
This radiograph shows a right retrograde pyelogra...

This radiograph shows a right retrograde pyelogram demonstrating a large filling defect in the mid-ureter due to transitional cell carcinoma (large arrow). Note the characteristic appearance of radiographic contrast material just distal to the obstruction (small arrow), which gives rise to the so-called goblet sign. Contrast is also visible beyond the partially obstructed segment of the ureter in the renal pelvis and collecting system.

Urothelial tumor of the renal pelvis (white arrow...
(Enlarge Image)
Media file 5: Urothelial tumor of the renal pelvis (white arrows), pathology specimen.
[ CLOSE WINDOW ]
Urothelial tumor of the renal pelvis (white arrow...

Urothelial tumor of the renal pelvis (white arrows), pathology specimen.

More on Transitional Cell Carcinoma, Renal

Overview: Transitional Cell Carcinoma, Renal
Differential Diagnoses & Workup: Transitional Cell Carcinoma, Renal
Treatment & Medication: Transitional Cell Carcinoma, Renal
Follow-up: Transitional Cell Carcinoma, Renal
Multimedia: Transitional Cell Carcinoma, Renal
References
[ CLOSE WINDOW ]

References

  1. Boorjian S, Ng C, Munver R, et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology. Aug 2005;66(2):283-7.

  2. Chen GL, Bagley DH. Ureteroscopic surgery for upper tract transitional-cell carcinoma: complications and management. J Endourol. May 2001;15(4):399-404; discussion 409. [Medline].

  3. Chew BH, Pautler SE, Denstedt JD. Percutaneous management of upper-tract transitional cell carcinoma. J Endourol. Jul-Aug 2005;19(6):658-63.

  4. Clark PE, Streem SB. Endourologic management of upper tract transitional cell carcinoma. ScientificWorldJournal. Jun 7 2004;4 Suppl 1:62-75.

  5. Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer. Jul 1 2003;98(1):55-60. [Medline].

  6. Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol. Jul 2002;42(1):43-8. [Medline].

  7. Gettman MT, Segura JW. Endourological management of upper tract transitional cell carcinoma. BJU Int. Dec 2003;92(9):881-5. [Medline].

  8. Goh M, Montie JE, Wolf SJ, Jr. Urothelial carcinoma of the upper urinary tract. In: Gillenwather JY, Grayhack JT, Howards Ss, Mitchell ME, eds. Adult and Pediatric Urology. Philadelphia: Lippincott Williams & Wilkins. 2002;Vol. 1, 4th ed:Chapter 17.

  9. Ho KL, Chow GK. Ureteroscopic resection of upper-tract transitional-cell carcinoma. J Endourol. Sep 2005;19(7):841-8.

  10. Holmang S, Johansson SL. Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology. Aug 2005;66(2):274-8.

  11. Hsueh TY, Huang YH, Chiu AW, et al. A comparison of the clinical outcome between open and hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. BJU Int. Oct 2004;94(6):798-801.

  12. Ignjatovic I, Dinic L, Prjiv B, Stojkovic I. CT staging of the upper urinary tract urothelial tumors. Medicine and Biology. 2003;10:135-8.

  13. Johnson GB, Grasso M. Ureteroscopic management of upper urinary tract transitional cell carcinoma. Curr Opin Urol. Mar 2005;15(2):89-93.

  14. Kawauchi A, Fujito A, Ukimura O, et al. Hand assisted retroperitoneoscopic nephroureterectomy: comparison with the open procedure. J Urol. Mar 2003;169(3):890-4; discussion 894. [Medline].

  15. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. Aug 2003;47(2):155-69. [Medline].

  16. Matin SF. Radical laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: current status. BJU Int. Mar 2005;95 Suppl 2:68-74.

  17. McCaffrey JA, Herr HW. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma. Surg Oncol Clin N Am. Oct 1997;6(4):667-81. [Medline].

  18. Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am. May 1993;20(2):333-47. [Medline].

  19. Messing EM. Urothelial tumors of the renal pelvis and ureter. In: Walsh PC, Retik AB, Vaughan ED, Wein AG, eds. Campbell's Urology. Philadelphia: Saunders. 2002;Vol 4:2765-84.

  20. Michaelson MD, Kaufman DS, Oh WK. Transitional cell carcinoma of the upper uroepithelial tract. Clin Adv Hematol Oncol. Feb 2003;1(2):102-4; discussion 105.

  21. Ong AM, Bhayani SB, Pavlovich CP. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol. Oct 2003;170(4 Pt 1):1301. [Medline].

  22. Pohar KS, Sheinfeld J. When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter?. J Endourol. May 2001;15(4):405-8; discussion 409. [Medline].

  23. Sagalowsky AI, Jarrett TW. Management of urothelial tumors of the renal pelvis and ureter. In: Walsh PC, Retik AB, Vaughan ED, Wein AG, eds. Campbell's Urology. Philadelphia: Saunders. 2002;Vol 4:2845-75.

  24. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol. Mar 1988;139(3):475-7. [Medline].

  25. Srinivas S, Guardino AE. A nonplatinum combination in metastatic transitional cell carcinoma. Am J Clin Oncol. Apr 2005;28(2):114-8.

  26. Stewart GD, Bariol SV, Grigor KM, et al. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int. Apr 2005;95(6):791-3.

  27. Wang SS, Ho HC, Su CK, et al. Seeding of malignant renal tumor through a nephrostomy tract. J Chin Med Assoc. Jun 2004;67(6):308-10. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

renal transitional cell carcinoma, TCC, renal urothelial carcinoma, urothelial carcinoma, UC, renal pelvis, papillary tumor, renal pelvic tumor, bladder tumor, bladder cancer

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Georgi Guruli, MD, PhD, Consulting Staff, Department of Surgery, Division of Urology, University Hospital; Assistant Professor, Department of Surgery, Division of Urology, UMDNJ - New Jersey Medical School
Georgi Guruli, MD, PhD is a member of the following medical societies: American Association for Cancer Research and American Urological Association
Disclosure: Nothing to disclose.

Coauthor(s)

Badrinath R Konety, MD, Associate Professor, Department of Urology, University of California at San Francisco
Badrinath R Konety, MD is a member of the following medical societies: American College of Surgeons, American Urological Association, and International College of Surgeons
Disclosure: Nothing to disclose.

Medical Editor

Michael C Perry, MD, Professor, Department of Internal Medicine, Nellie B Smith Chair of Oncology, Director, Division of Hematology and Oncology, University of Missouri at Columbia/Ellis Fischel Cancer Center
Michael C Perry, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Missouri State Medical Association, Southern Association for Oncology, and Southern Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Wendy Hu, MD, Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center
Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Physicians for Social Responsibility
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

John S Macdonald, MD, Professor of Medicine, New York Medical College; Chief, Division of Medical Oncology, St Vincent's Hospital and Medical Center; Medical Director, Saint Vincent's Comprehensive Cancer Center
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.